NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE
Delisted
NBSE was delisted on the 10th of May, 2024.
38 hedge funds and large institutions have $2.52M invested in NeuBase Therapeutics, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
38
Holders Change
-2
Holders Change %
-5%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
7
Reduced
7
Closed
8
Calls
$3K
Puts
$8K
Net Calls
-$5K
Net Calls Change
+$49K
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$226K |
| 2 |
CC
Cannell & Co
New York
|
+$187K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$39.9K |
| 4 |
Goldman Sachs
New York
|
+$39K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
+$29.6K |
Top Sellers
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$530K |
| 2 |
B
Bailard
Foster City,
California
|
-$373K |
| 3 |
BlackRock
New York
|
-$67.6K |
| 4 |
New York State Common Retirement Fund
Albany,
New York
|
-$34K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$34K |
